본문 바로가기

Main Tasks

A vision-driven and value-generating global healthcare group

  • Home
  • R&D
  • Main Tasks

Main Tasks

  • Lasmiditan

    Innovative Migraine Treatment

    • Original Developer : CoLucid Pharmaceuticals (acquired by Lilly in Jan 2017)
    • Mechanism of Action : A 5-HT1F (serotonin) ditan drug for the treatment of acute migraines.
    • Features : Whereas conventional triptan drugs are associated with cardiovascular contraction due to the actions of 5-HT1B,D as one of their side effects, Lasmiditan differs in that it acts quickly with minimal side effects. (an alternative treatment for migraine sufferers diagnosed with or at the risk of developing a cardiovascular disease)
    • Schedule : License application in 2018 (tentative)
    • Licensing : Completed in 2013, distribution rights in South Korea and eight ASEAN countries.
  • Targeted Agent (IDX1197)

    Personalized Tumor Treatment through Inhibition of the PARP-1 Protein

    • A targeted anticancer drug that prevents the survival and maintenance of cancer by inhibiting the damage-recovery system of cancer cells (PARP1).
    • Proven superior anticancer properties against HRD-related ovarian cancer, pancreatic cancer, breast cancer, and prostate cancer.
    • Patents: Patents filed in 14 countries (US, Europe, Russia, China, and Japan).
    • Best in Class (cf. AstraZeneca “Lynparza” (Ingredient: Olaparib))
  • Biobetter (IDB-0062)

    Next-Gen Eye Disease Treatment

    • A safe, Lucentis-based biobetter.
    • Possibility of increased efficacy, resistance elimination, and improved patient convenience through fusion of functional peptides.
    • Possible to administer on patients who are resistant to or do not respond to Lucentis and possible to expand indication to include diabetic retinopathy.
    • Possibility of future development as eye drops through formulation improvements confirmed.
  • Biobetter (IDB-0072)

    New Dual-Target Antibody Cancer Drug

    • Avastin-based biobetter.
    • Able to treat non-responsive and resistant patients through suppression of various vascular endothelial growth factors and vessel stabilization.
    • Reduced dose for lower possibility of side effects and increased cost-effectiveness.
    • Potential applications with anticancer drugs whose indications have been revoked due to lack of efficacy.
TOP